Saturday 17 October 2026
Export BOLD’s income statement to Excel — free account
Boundless Bio, Inc.
BOLD Healthcare Biotechnology
In the quarter to June 2026, EPS fell 51.4%, free cash flow fell 76.9% and total debt fell 6.85%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.34
0.01
−0.43%
Follow BOLD
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 2.33 | 1.00 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 15.24 | 3.12 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 72 | 64 | 28 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | (46) | (49) | (65) | (58) | |||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | (46) | (49) | (65) | (58) | |||||
| Depreciation | — | — | — | — | — | — | 1 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | (41.80) | (40.65) | (3.85) | (2.60) | |||||
| Cash flow | — | — | — | — | — | — | (36.06) | (38.53) | (3.58) | (2.09) | |||||
| Capex | — | — | — | — | — | — | (0.97) | (0.52) | (0.15) | (0.02) | |||||
| Free cash flow | — | — | — | — | — | — | (37.03) | (39.05) | (3.73) | (2.11) | |||||
| Book value | — | — | — | — | — | — | 60.34 | 99.12 | 8.87 | 4.41 | |||||
| Shares, m | — | — | — | — | — | — | 1 | 1 | 17 | 22 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (40) | (47) | (61) | (47) | ||||
| Capex | — | — | — | — | — | — | (1) | (1) | (3) | (1) | |||||
| Free cash flow | — | — | — | — | — | — | (41) | (47) | (63) | (47) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 60 | 115 | 146 | 97 | ||||
| Total debt | — | — | — | — | — | — | 3 | — | 48 | 46 | |||||
| Net debt | — | — | — | — | — | — | (64) | (121) | (104) | (62) | |||||
| Shareholders’ equity | — | — | — | — | — | — | 66 | 121 | 151 | 99 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (47.83) | (38.87) | (32.02) | ||||
| ROIC | — | — | — | — | — | — | (1,221.33) | 0.00 | (99.20) | (107.52) | |||||
| ROE | — | — | — | — | — | — | 0.00 | 47.36 | (554.86) | (46.69) | |||||
Negative figures in brackets.
Charts ten years each
Boundless Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ALPS Alps Group Inc. | $56.4M | — (loss-making) | — | — | n/m | −26.48% (below 0%: shrinking) | — | 0.00% | Compare |
| ELOX Senesco Technologies Inc. | $55.3M | — (loss-making) | — | — | n/m | −144.34% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| GUTS Fractyl Health, Inc. | $55.2M | — (loss-making) | — (loss-making) | −57.14% (below 0%: shrinking) | n/m | +25.34% (above 0%: growing) | 100.00% | 0.00% | Compare |
| GOSS Gossamer Bio, Inc. | $54.3M | — (loss-making) | — (loss-making) | −19.59% (below 0%: shrinking) | n/m | +16.32% (above 0%: growing) | 100.00% | (282.25%) | Compare |
| RNTX Rein Therapeutics Inc. | $54.2M | — (loss-making) | — | — | n/m | −34.62% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RNXT RenovoRx, Inc. | $53.7M | — (loss-making) | — (loss-making) | +115.40% (above 0%: growing) | n/m | −27.63% (below 0%: shrinking) | 84.27% | (368.43%) | Compare |
| BOLD Boundless Bio, Inc. | $53.5M | — (loss-making) | — | — | n/m | −76.90% (below 0%: shrinking) | — | 0.00% | |
| ATHE Alterity Therapeutics Limited - Sponsored ADR | $52.0M | — (loss-making) | — | — | 0.00% | −84.83% (below 0%: shrinking) | 0.00% | — | Compare |
| INKT MiNK Therapeutics, Inc. | $50.7M | — (loss-making) | — | — | n/m | −32.73% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $54.2M | — | — | −19.59% | — | −30.18% | 84.27% | 0.00% |
Boundless Bio, Inc. (BOLD) key facts
- Boundless Bio, Inc. (BOLD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, BOLD traded at $2.34, a market capitalization of $53.5 million.
- Return on equity was −46.7% and debt-to-equity 0.00.
Boundless Bio, Inc. (BOLD) Latest News
No news at this impact. Lower the threshold for more.